Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Russell F. DeVore"'
Autor:
David H. Johnson, Roy S. Herbst, Corey J. Langer, Louis Fehrenbacher, William Novotny, Eric Holmgren, Jacques Gaudreault, John Nemunaitis, David M. Jablons, Fairooz F. Kabbinavar, Russell F. DeVore, Lisa A. Damico
Publikováno v:
Journal of Clinical Oncology. 41:2305-2312
Purpose To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and Methods In a phase II trial, 99 patients were randomly assigned to bevacizum
Autor:
Kathy Miller, Russell F. DeVore, Gregory A. Masters, Charles D. Blanke, Lieven Declerck, Alan Sandler, David H. Johnson
Publikováno v:
Journal of Clinical Oncology. 21:1550-1555
Purpose: Gemcitabine has shown a broad range of activity in solid tumors, including previously untreated small-cell lung cancer (SCLC). The objective of this phase II trial was to investigate the activity of gemcitabine in patients with relapsed SCLC
Publikováno v:
Journal of Clinical Oncology. 19:2114-2122
PURPOSE: To determine the efficacy of topotecan in combination with standard chemotherapy in previously untreated patients with extensive-stage small-cell lung cancer (SCLC), the Eastern Cooperative Oncology Group (ECOG) conducted a phase III trial.
Autor:
Larry Schlabach, Yu Shyr, Hak Choy, David H. Johnson, Lester Porter, Kenneth R. Hande, Russell F. DeVore, Furhan Yunus, Paul Rosenblatt, Clyde Smith
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 47:931-937
Purpose: We conducted a prospective phase II study to determine the response rate, toxicity, and survival rate of concurrent weekly paclitaxel, carboplatin, and hyperfractionated radiation therapy (paclitaxel/carboplatin/HFX RT) followed by 2 cycles
Autor:
Jin Soo Lee, Vincent A. Miller, Everett E. Vokes, David R. Gandara, Melvin Moore, Francis Gamza, Frank Dunphy, Jeffrey Crawford, Luz Hammershaimb, Daniel D. Karp, Ronald R. Natale, Frank V. Fossella, Russell F. DeVore, Yong Kim, Ronald N. Kerr, Mark G. Kris, L A Kalman
Publikováno v:
Journal of Clinical Oncology. 18:2354-2362
PURPOSE: To confirm the promising phase II results of docetaxel monotherapy, this phase III trial was conducted of chemotherapy for patients with advanced non–small-cell lung cancer (NSCLC) who had previously failed platinum-containing chemotherapy
Publikováno v:
Cancer Control. 4:317-325
BackgroundNon-small-cell carcinoma of the lung has long been considered a chemotherapeutically resistant neoplasm. Newer agents and combinations are being tested.MethodsThe authors have reviewed data on recent and active phase I and phase II trials o
Autor:
Leora Horn, Yu Shyr, Steven N. Wolff, Janessa Laskin, Alan Sandler, Russell F. DeVore, Zhiguo Zhao, David P. Johnson
Publikováno v:
Clinical lung cancer. 12(3)
Objectives Our study set out to determine the antitumor efficacy of carboplatin and irinotecan as assessed by response rate in persons with chemotherapy-naive extensive-disease, small-cell lung cancer (ED-SCLC). Secondary objectives included progress
Publikováno v:
Oncology. 49:57-62
Forty-two patients with unresectable non-small cell lung cancer (NSCLC) were treated with carboplatin (300, 350 or 400 mg/nr) and 21 days of oral etoposide (50 mg/m2/day). Thirty-three pati
Autor:
X. Jia, John V. Heymach, Steven Zhang, Bruce E. Johnson, David H. Johnson, Howard Safran, Russell F. DeVore, F. Yunus, Fadlo R. Khuri, H. M. Richards, P. M. De Porre, L. L. Schlabach
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 15(8)
Background: R115777 (tipifarnib, Zarnestra™) is a farnesyl transferase inhibitor that blocks the farnesylation of proteins involved in signal transduction pathways critical for cell proliferation and survival. This multicenter phase II study was co
Autor:
Philip Bonomi, James R. Jett, James D. Luketich, Russell F. DeVore, David H. Johnson, Tracey W. Dobbs, Lewis J. Cohen, Chandra P. Belani, David S. Ettinger
Publikováno v:
Europe PubMed Central
We examined the safety and efficacy of the docetaxel/cisplatin combination in patients with advanced, previously untreated NSCLC and evaluated changes in quality of life over time. Docetaxel was administered before cisplatin (both 75 mg/m2, 1-hour in